Last reviewed · How we verify
High-dose oxytocin
At a glance
| Generic name | High-dose oxytocin |
|---|---|
| Sponsor | Ohio State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor (PHASE4)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- The Effect of Oral Oxytocin and Atosiban on Social Attention (EARLY_PHASE1)
- Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor (PHASE4)
- Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (PHASE2)
- Dose Response Relationship of Oxytocin on Irritability in Youths (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (PHASE2)
- High Or Low Dose pOstpartUm Oxytocin at the Time of Cesarean Birth (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose oxytocin CI brief — competitive landscape report
- High-dose oxytocin updates RSS · CI watch RSS
- Ohio State University portfolio CI